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Introduction 
Pantothenate kinase-associated neurodegeneration (PKAN, formerly Hallervorden–
Spatz syndrome, OMIM #234200) is the most common neurodegeneration with 
brain iron accumulation (NBIA) disorder, with an estimated incidence of 1-3 per 
million1 and accounting for about half of NBIA cases.2 As is the case for most rare 
disorders, evidence-based guidance for the clinical management of PKAN is limited, 
often relying instead on anecdotal evidence, case reports and small series studies. 
Despite the small number of geographically dispersed people with PKAN, clinicians 
with concentrated experience have developed opinions and expertise about their 
optimal care. Moreover, family members and affected individuals themselves 
develop substantial personal experience in meeting their needs. In this document 
we have amalgamated such professional expertise, lay experiences and published 
data into a consensus guideline. This guideline summarizes what we believe are 
current best practices and therapeutic approaches for the care of people with PKAN 
and their families. 
 
Methods 
This guideline largely reflects the consensus opinion of clinical experts in PKAN. In 
addition, peer-reviewed publications were systematically searched for, evaluated, 
and their conclusions incorporated into this document when applicable. PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) was searched January - February 2016 
using the following search terms: ‘PKAN’, ‘pantothenate kinase-associated 
neurodegeneration’, ‘HSS’, ‘Hallervorden-Spatz syndrome’, ‘NBIA’, and 
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‘neurodegeneration with brain iron accumulation.’ Limited consideration was made 
of publications utilizing aggregated data from multiple NBIA disorders or in which a 
diagnosis of PKAN could not be confirmed based on the information provided. 
A draft guideline was developed and submitted for review in four phases (approved 
by the OHSU IRB as protocol e8165). The first was to an international group of 
clinical experts, each with more than 10 years of experience with PKAN. Based on 
their recommendations, revisions were made and a second phase of review was 
sought by leaders of international patient advocacy groups. After further revisions 
were incorporated, a draft was shared with people with PKAN and their family 
members from nine affected families who commented further. Finally, an open call 
to the NBIA community was made via the NBIAcure.org website for final reviews 
and comments. 
Role of the funding source 
Leaders and members of the non-profit lay advocacy organizations that funded this 
work reviewed and edited this manuscript but had no other role in this work. 
 
Diagnosis and initial care 
The diagnosis of PKAN is usually considered on the basis of clinical suspicion and 
radiological data. Often, the clinical features are suggestive, and the diagnosis 
becomes strongly suspected after the characteristic brain MRI pattern is revealed. 
Since the PANK2 gene discovery3, the phenotypic spectrum of PKAN has broadened, 
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and with it, the range of presenting features. Greater access to early neuroimaging 
using MRI sequences that are sensitive to iron and to clinical whole exome 
sequencing can significantly reduce the time to diagnosis of people with early 
clinical manifestations.  
Classic PKAN: presenting features 
Classic PKAN defines the group of people with the youngest age at onset and most 
rapid rate of disease progression. The natural history of classic PKAN is relatively 
homogeneous. Onset in classic PKAN occurs before 6 years of age in 90% (range: 6 
months-12 years, mean: 3 years 4 months).2 The main presenting features are limb 
dystonia and spasticity, clumsiness with frequent falls. While retinopathy is 
common, clinically significant visual impairment usually lags behind the 
neurological manifestations. Earlier histories of developmental delay, ADHD, or toe-
walking also are common.  
Atypical PKAN: presenting features 
Atypical PKAN is an inclusive term for all non-classic PKAN phenotypes. The 
spectrum of atypical PKAN is broad and more accurately encompasses a continuum 
from classic disease. Disease onset is in later childhood, adolescence or adulthood 
(age range: 1–28 years, mean age: 13 years 8 months),2,4 and the rate of progression 
is slower. Atypical PKAN often presents with neuropsychiatric or speech problems 
followed later by the development of dystonia or parkinsonism, sometimes 
superimposed on a history of attention deficit hyperactivity disorder (ADHD). 
Action-induced jaw dystonia occurring with eating or speaking is an unusual clinical 
feature that should always prompt consideration of the diagnosis of PKAN. Similarly, 
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truncal opisthotonus is common in both classic and atypical disease and is highly 
suggestive of PKAN. 
Diagnostic MRI 
People suspected to have PKAN based on clinical features should undergo brain MRI 
using iron sensitive sequences such as SWI, GRE, T2* as a first line diagnostic 
investigation to identify the characteristic changes.2 The MRI abnormality, called the 
‘eye-of-the-tiger’ sign, is observed on T2-weighted imaging and consists of 
hypointense signal in the globus pallidus surrounding a region of hyperintense 
signal (Figure 1).5 This pattern is found in both classic and atypical disease, though 
occasionally people with PKAN will lack this finding.6-8 MRI changes are usually 
evident by 3-4 years of age in classic disease if iron-sensitive sequences are 
employed and may be present much earlier. By the time clear neurologic features 
are present, the brain MRI almost always shows characteristic changes.  If the brain 
MRI is not typical for PKAN in a person strongly suspected to have this disorder, 
genetic testing is indicated. 
Genetic testing 
When PKAN is suspected, genetic testing is recommended in order to confirm the 
diagnosis. Sequencing and deletion/duplication analyses of the PANK2 gene, which 
is mutated in PKAN, are needed for a complete analysis. Genetic information is 
valuable for predicting prognosis, facilitating prenatal or pre-implantation genetic 
diagnosis in future pregnancies, and identifying other carriers in the family. Clinical 
genetic testing laboratories may be found worldwide through local medical genetics 
or neurology professionals. NBIA gene panels are now available at select labs and 
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may be a more efficient and cost-effective option in some situations.  For people for 
whom genetic testing is not possible, reasonable confidence in the diagnosis can 
often be established when characteristic clinical and radiographic changes are 
documented. In cases where only one PANK2 mutation is identified, experts can help 
establish a confident diagnosis based on clinical and MRI data. 
Other recommended care at the time of diagnosis 
 Neurology – Establishing care with a neurologist is important to document the 
individual’s baseline at the time of diagnosis and facilitate subsequent 
interventions as needed, such as initiating treatment with medication or referral 
to physical or other therapies. Given the progressive nature of the disease, a 
good relationship with open communication between the neurologist and family 
is key.  A child neurologist is appropriate for children; a movement disorders 
neurologist is a good choice to manage adults and some older children with 
PKAN.  Co-management with a rehabilitation medicine physician is optimal in 
countries where this specialty expertise is available. 
 Ophthalmology – Clinical eye examination is recommended to assess visual 
function since retinopathy is common, especially in children with classic PKAN. 
Electroretinography (ERG) is not needed to guide clinical management in most 
people. 
 Brain MRI - If a diagnosis of PKAN is confidently established on the basis of 
genetic data prior to obtaining a brain MRI (e.g. by whole exome sequencing), we 
suggest performing a brain MRI only if the results will impact medical decision-
making. Conversely, imaging may confirm or exclude a diagnosis of PKAN when 
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clinical and genetic data are equivocal. 
 Genetic counseling - Genetic counseling is important in the early care of families 
with a new diagnosis of PKAN and can identify other family members at risk of 
being affected or being PANK2 mutation carriers.  Since PKAN is an autosomal 
recessive disorder, each full sibling has a 1-in-4, or 25%, chance of being 
affected. Discussion about diagnostic evaluation in siblings of a proband is a 
priority, especially when they are younger or share abnormal features with their 
affected sister or brother.  In this instance, assessment by neurological exam, 
MRI or diagnostic genetic testing should be considered.  Healthy, unaffected 
siblings have a 2-in-3 chance of being carriers and can consider carrier testing 
when they become adults.  Genetic testing is recommended only for 
symptomatic siblings. Genetic counselors can also connect families to the PKAN 
family community and to the lay advocacy network, the NBIA Alliance. 
 Other testing – Other manifestations of PKAN include acanthocytosis and 
abnormal spermatogenesis, neither of which warrants investigation in most 
individuals at the time of diagnosis. Acanthocytosis is difficult to confidently 
establish in the clinical lab, and its presence does not guide further care. 
 Rehabilitation therapy – Disabling physical, occupational or speech problems 
should be addressed as early as possible after diagnosis in order to preserve 
function. 
 Family support – Psychosocial care and counseling should be offered to families 
and to affected persons as soon as possible after diagnosis. Social counseling and 
guidance can provide families with important information about benefits 
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available for disabled persons that may help to prepare them for any adaptations 
needed for daily activities. 
 
Disease progression in PKAN 
PKAN is a progressive neurodegenerative disorder affecting movement, balance, 
speech, vision, cognition, affect and behavior. In classic PKAN, most children lose the 
ability to ambulate independently and safely by age 10 years. The pattern of 
progression is saltatory, with step-wise decline occurring over a few days or weeks, 
followed by plateauing that may be sustained for weeks or months. In general, 
motor skills that have been lost are not regained. The overall trajectory of change is 
that of relentless progression, and no clear exacerbating factors have been identified 
to account for the periods of more precipitous decline. This pace continues until the 
child loses all independent function, typically during the second decade. Despite the 
severe degree of motor impairment, children with PKAN retain the cognitive 
abilities that they attain during development. Some children, especially those with 
very young onset of disease, do have significant intellectual and developmental 
disabilities, but they do not lose cognitive skills in tandem with motor function. 
In classic PKAN, severe dystonia and postural instability leading to frequent falls 
cause the most disability, complications and pain. Dystonia leads to stridor, extreme 
opisthotonic posturing, bone fractures, joint dislocation and recurrent tongue-
biting. The resulting pain and distress can precipitate a vicious cycle and lead to 
status dystonicus. Other secondary complications include airway obstruction, 
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orthopedic deformity and infection. 
Atypical PKAN progresses more slowly, and some individuals experience plateauing 
of symptoms for many months, years or even decades. Static disease or minimal 
progression over 5-10 years is not uncommon for people with atypical PKAN. One 
study of 9 individuals with atypical PKAN suggested that the majority of significant 
symptoms developed during the first 5 years, followed by a relatively stable phase 
of slower progression9 —a pattern that has also been observed by the authors.  
Although dystonia is also prominent in atypical PKAN, parkinsonism usually 
contributes more significantly to the disability as disease advances, and dysarthria 
has a significant impact on quality of life. Unlike dystonia in the disease, the 
parkinsonism of PKAN is relatively symmetric, usually with significant postural 
instability, little tremor, and variable bradykinesia and rigidity. 
Variability is observed within families; however, most affected siblings are 
phenotypically concordant and their disease typically advances at a similar rate. 
Adults with PKAN have graduated from college, served in the armed forces, married 
and raised children. The range and spectrum of disability is very wide. 
The clinical exam is most useful in gauging progression and in guiding ongoing 
management. Moreover, MRI in children requires sedation and is not without risk. 
We recommend against regular brain MRI in PKAN unless the results would guide 
specific medical decision-making.  
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Treatment and ongoing management and surveillance  
Rational therapeutics 
Although there currently is no disease-modifying therapy for PKAN, rational 
therapeutics that target the primary biochemical defect are in development.3,10 For 
now, medication management is primarily symptomatic, and ongoing care follows 
general recommendations developed for people with a chronic progressive disease.  
 
Vitamin B5 (pantothenate) and related compounds  
PKAN is an inborn error of coenzyme A biosynthesis. Pantothenate forms the 
chemical backbone of coenzyme A, which is essential for hundreds of biochemical 
reactions essential for health. Pantothenate was hypothesized to be a potential 
therapeutic for PKAN based on the concept of enzymatic substrate overload.3 This 
idea presumes at least partial PANK2 enzyme function, which is predicted to occur 
in people with atypical PKAN but not in those with classic disease. However, 
because of its low toxicity, pantothenate has been tried by many people with classic 
and atypical PKAN to determine if it might have benefit. No clinical trial has been 
performed to evaluate the efficacy of pantothenate. 
Regardless of phenotype, we recommend consideration of a trial of high dose 
pantothenate for at least 3 months for all people with PKAN, starting at a dose of 
250 mg orally and increasing weekly by 500mg until a daily dose of 2-5 grams is 
reached or side effects become evident. Based on anecdotal experience, 
pantothenate is well-tolerated with few side effects. Some adults with atypical PKAN 
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perceive benefit from pantothenate to their gait, speech and clarity of thinking. For 
most children with classic PKAN, pantothenate seems to offer little or no benefit, 
and the volume of the compound may be challenging to administer to a child. For 
those perceiving no benefit, we recommend discontinuing the vitamin supplement. 
Compounds that bypass the defective PANK2 enzyme, including pantetheine, 
phosphopanthetheine, and coenzyme A and their derivatives, have shown promise 
in ameliorating various manifestations of defective pantothenate kinase 2 in disease 
models investigated in the research laboratory.10-12 Anecdotal reports of oral 
pantetheine supplementation have suggested possible improvement in attention in 
some people with PKAN while others have observed no benefit. Studies are 
underway to assess the safety and therapeutic efficacy of several intermediary 
compounds.  
 
Iron-chelating agents, including deferiprone 
The role that iron plays in PKAN pathogenesis is still unclear because iron 
dyshomeostasis is a secondary phenomenon in this disorder. Nevertheless, high 
iron levels develop in globus pallidus and probably contribute to cell and tissue 
damage. The utility of iron chelators has been limited by systemic iron depletion.13 
Newer agents more readily cross the blood-brain barrier yet have a lower affinity 
for iron, thereby minimizing systemic iron loss. Deferiprone is one agent under 
study in PKAN, and preliminary data support its effectiveness in lowering brain iron 
levels as measured by MRI; however, convincing evidence of clinical benefit is 
lacking.14,15 An international randomized, double-blind, placebo-controlled study to 
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assess the safety, tolerability and efficacy of deferiprone in PKAN is underway 
(clinicaltrials.gov/ct2/show/NCT01741532). Results of this trial will be known in 
early 2017. 
 
Symptom-based interventions 
Medications 
Dystonia is the most disabling motor symptom for the majority of people with 
PKAN. Over time, dystonia affects more body regions and typically worsens in those 
regions affected. Motor symptoms in PKAN are often mixed, manifesting with 
dystonia, spasticity and parkinsonism. Therefore the main treatment goal is relief of 
the most disabling symptoms with the aim to minimize both disability and off-target 
effects as much as possible. 
Dystonia and spasticity are usually managed with anticholinergics, benzodiazepines 
and other anti-spasticity agents, alone or in combination, as symptoms dictate. For 
focal dystonia, botulinum toxin [1] injections can also provide targeted relief of 
dystonia and spasticity. The first-line drugs that are most commonly effective in PKAN 
are trihexyphenidyl, clonazepam, and baclofen. If dystonia dominates the phenotype, 
we recommend starting treatment with trihexyphenidyl; if spasticity is prominent, 
with baclofen. Clonazepam may be added for troublesome breakthrough spasticity 
or dystonia that is not relieved with the first two medications. Second-line drugs for 
                                                        
[1] Pediatric Use: Safety and efficacy are not established in patients under 18 years 
of age for the treatment of upper limb spasticity, in patients under 16 years of age 
for the treatment of cervical dystonia, and in patients under 12 years of age for the 
treatment of blepharospasm and strabismus. 
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PKAN include clonidine, gabapentin, tetrabenazine, and pregabalin. Where 
symptoms are not adequately controlled with first-line drugs, we recommend a trial 
of these medications with taper and discontinuation if no benefit is observed after 
two weeks at the target dose.  
We recommend that, where feasible, drugs be introduced one at a time at a low 
starting dose and increased gradually to an efficacious dose or to tolerability, 
whichever occurs first. If a specific medication provides no clear benefit by 4-6 
weeks after achieving the target dose, the drug may be withdrawn gradually. 
Children generally tolerate significantly higher doses of these drugs than adults and 
may require same to achieve relief of symptoms. A corollary is that a previously 
well-tolerated drug regimen may cause adverse effects as the child with PKAN 
moves into adolescence and adulthood; this is especially true of 
anticholinergics.  Therefore we recommend a critical review of an established drug 
regimen annually, with directed questions regarding adverse effects predicted from 
the specific drugs included in the regimen. 
PKAN-associated dystonia and even the parkinsonism observed in older individuals 
with PKAN are rarely responsive to dopaminergic medications.  Most people with 
PKAN have had a trial of levodopa at some point in their disease and very few report 
any benefit. Similarly, dopamine agonists seem to be of limited utility in the disease. 
Interestingly, some adults with PKAN do report improvements in postural 
instability with amantadine.  We do not recommend dopaminergic drugs as first line 
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agents for symptom management in PKAN; however, a trial of amantadine should be 
considered in adults with postural instability.  
Agents to avoid 
Anecdotal reports of three siblings with atypical PKAN treated with alpha-
tocopherol (vitamin E), selenium, and idebenone indicated precipitous worsening of 
symptoms, with subsequent improvement once these compounds were stopped.16 
Therefore we recommend avoiding these compounds, including as nutritional 
supplements, unless there is a specific medical indication for their use in a person 
with PKAN. 
 
Surgical procedures, sedation and anesthesia 
Anesthesia for procedures in individuals with PKAN should be undertaken only when 
absolutely necessary and with close collaboration between the primary provider and 
anesthesia and surgical teams.  Adequate post-operative pain and dystonia 
management are critical. Pre-existing neck and oromandibular dystonia may 
complicate both awake and sedated intubation, and for reasons that are unclear, 
procedures with anesthesia may precipitate an acute exacerbation of dystonia in 
people with PKAN. This phenomenon has been observed even with light anesthesia 
and with a variety of anesthetic agents; however, it is difficult to attribute changes 
specifically to the anesthesia rather than to the indication for a procedure. 
Acute dystonic reactions to anesthetic agents such as propofol have been reported 
in previously healthy adults and therefore this drug tends to be avoided in people 
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with movement disorders;17 however, there is no evidence that people with PKAN 
are more vulnerable to this anesthetic complication than the general population and 
in fact, propofol has been used successfully in PKAN in case reports.18-20 
Intrathecal and intraventricular baclofen therapy  
The administration of baclofen into the central nervous system for dystonia and 
spasticity may provide greater efficacy and cause fewer systemic side effects than 
oral dosing. We recommend starting with oral baclofen, increasing the dose as 
symptoms require. Once the maximum oral dose fails to control symptoms or causes 
unacceptable adverse effects, central dosing should be considered. Better outcomes 
have been observed in those with lower extremity symptoms who are still 
ambulatory; the gravity-dependence of drug delivered into the intrathecal space 
may preserve ambulation for longer in this situation. The approach seems to have 
less robust effects on opisthotonus in non-ambulatory people than might be 
expected. Usually a test intrathecal dose is administered in the outpatient setting to 
judge response before committing to implantation of the pump. Standard 
procedures for test dosing and for catheter and reservoir placement should be used. 
Over time, trials of continuous infusion with or without added bolus dosing may be 
considered to optimize function and minimize discomfort. As with all medications, 
dosing needs are likely to change over time. Skin breakdown around an indwelling 
device is a risk for those whose dystonia causes pressure and abrasion to the 
overlying skin, but problems of frequent catheter kinking and life-threatening drug 
withdrawal in the setting of opisthotonus have not been observed. Among the most 
important considerations for any surgical procedure, including pump placement, is 
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the experience and record of success of the performing surgeon. Therefore, we 
strongly encourage families to request this information to enable them to make an 
informed decision. 
Intraventricular administration of baclofen is reported to be as safe as intrathecal 
dosing21-23 and requires even lower doses;21 however, experience with this 
approach is limited in PKAN. In theory, intraventricular dosing may offer 
advantages over intrathecal administration to those with head, neck and upper body 
dystonia, but this has not been specifically studied. 
 
Deep brain stimulation (DBS)  
Dystonia relief from DBS has been mixed in PKAN, similar to the experience in other 
secondary dystonias. Numerous case reports and series that include mixed NBIA 
etiologies report benefit for many people in the first year or years with placement in 
the globus pallidus interna; however, benefit usually is not sustained as disease 
advances, and cases with little or no clinical benefit are less likely to be published,24-
29 Adolescents and adults with atypical PKAN are more likely to benefit from DBS; 
we are unaware of children with classic PKAN who have had significant sustained 
benefit beyond a few months. While DBS is considered to be part of the current 
management arsenal for PKAN, there is no consensus about the efficacy of DBS in 
relieving dystonia in PKAN nor of the optimal candidate, timing in disease 
progression or stimulator settings. When DBS is considered, we recommend referral 
to an experienced DBS center for evaluation. A discussion of risks, benefits, 
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alternatives and realistic outcome goals is essential. Indwelling medical devices 
increase the risk for infections that can be difficult to treat. Other considerations 
that should guide decision-making include the person’s general health and the 
likelihood of their gaining relief from their most disabling symptoms. 
Recommendations for DBS electrode settings are guided by dystonia rather than the 
specific diagnosis of PKAN. A delay between settings changes and clinical response 
that may be as long as weeks to months is common in dystonia. Risk from DBS is not 
significantly different in children and adults with PKAN compared with what has 
been reported in other disorders.  
 
Thalamotomy and pallidotomy 
For severe disabling dystonia that is refractory to medical management, 
thalamotomy30 and pallidotomy18,31,32 have been performed in PKAN, sometimes 
with good symptomatic relief. Concerns have been raised about the irreversible 
nature of these procedures, especially in children and adolescents, and these 
ablative procedures have been largely replaced by deep brain stimulation. Despite 
this, in certain cases of refractory painful dystonia, this approach may provide relief 
to the person with PKAN. 
 
Rare movement disorders in PKAN 
Tics, chorea and myoclonus have been reported in PKAN33,34.  A diagnosis of a tic 
disorder or Tourette syndrome may precede that of PKAN, especially in children 
and adolescents. Treatment approaches, when indicated, should generally follow 
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standard medical management for such symptoms;35 however, we recommend that 
noradrenergic agents such as clonidine, guanfacine, and atomoxetine be considered as 
first-line agents for treatment of tic disorders over antipsychotics due to the latter 
class of drugs’ risk of inducing acute and tardive dystonia in a population where this 
would be hard to detect in the setting of dystonia due to PKAN. 
 
Status dystonicus 
The development of increasingly frequent or continuous severe episodes of dystonic 
spasms, referred to as “status dystonicus” or “dystonic storm”, is common in PKAN 
and demands urgent medical attention often requiring hospitalization. Most 
children and young adults with severe PKAN experience an episode of status 
dystonicus at least once during the course of their disease. Anytime there is a 
worsening of dystonia, aggressively assessing for and treating the common 
precipitants specific to PKAN is the highest priority. These include bone fracture 
(often atraumatic or minimally traumatic), occult bleeding or infection, and 
recurrent soft tissue trauma (tongue, lips, cheek biting). Early recognition of 
worsening of symptoms is key to averting progression to status dystonicus and to 
realizing a better outcome. The triggers, management and complications of status 
dystonicus in PKAN are similar to those in other disorders. Therefore, we 
recommend following the detailed general guidelines that have evolved over the past 
few years36, with exceptions described below for PKAN and detailed in figure 2. 
Use of a simplified dystonia severity action plan is recommend for all people with 
PKAN.28 A scale to assess risk of status dystonicus can help determine the level of 
07 Nov 2016 FINAL 20 
care required for management at any given stage, and management 
recommendations should be tailored to the individual. Common triggers in PKAN 
include rib, skull and long bone fractures (often occult), gastrointestinal bleeding, 
infection, joint injury or dislocation, fecal impaction, tongue-biting and respiratory 
compromise from stridor. Aggressively assessing for and treating these conditions is 
the first priority anytime there is a worsening of dystonia. Other common triggers 
include abrupt initiation or cessation of a medication, and anesthesia or surgery. No 
specific medications or anesthetic agents are contraindicated in PKAN based on 
rigorous data. 
Management of status dystonicus in PKAN must be guided by the individual’s 
underlying disease state. The first-line therapy is to start or increase antidystonic 
drugs, especially benzodiazepines. Intubation with deep sedation and surgical 
interventions, including DBS placement and ablative procedures such as 
pallidotomy, may be appropriate in a minority of people.37 L-dopa has little or no 
efficacy in relieving symptoms in most people with PKAN, and therefore is not 
recommended despite its use in management of status dystonicus associated with 
other etiologies. In addition, drugs with D2 antagonist activity, including high-
potency neuroleptics such as haloperidol and atypical antipsychotics such as 
risperidol, should be used with caution and for as short a period as possible because of 
their propensity to cause acute and tardive dystonia.38 
Laryngeal dystonia and stridor 
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Inspiratory stridor caused by adductor laryngeal breathing dystonia is a worrisome 
manifestation of PKAN in both children and adults.39 It may occur in isolation, but 
more often an underlying precipitant that is causing pain can be identified. Agitation 
from stridor can further exacerbate laryngeal dystonia and cause a cycle of 
increasing distress that can be difficult to interrupt and may precipitate generalized 
status dystonicus. Careful evaluation to systematically exclude a treatable cause for 
agitation is essential. Respiratory function must be monitored closely and is a 
critical factor in guiding the need for and type of intervention. Stridor may be 
tolerated in PKAN and may not necessitate intervention; however, if respiratory 
function is compromised or if agitation accompanies the stridor, then aggressive 
management is indicated to ease the dystonia and support respiration. For persistent 
laryngeal dystonia that interferes with respiration and oxygenation, botulinum toxin 
injections to bilateral thyroarytenoid muscles may provide relief but can take 
several days to manifest. Rarely, tracheostomy may need to be considered in 
consultation with an otolaryngologist.40,41 Once the stridor is relieved, respiratory 
function usually returns to normal. In PKAN, stridor often recurs. 
 
Multidisciplinary Management of PKAN 
Optimum symptomatic management of PKAN requires a multidisciplinary approach 
that focuses on anticipatory and preventive measures as well as active interventions 
to address secondary complications from the disorder. Implementing a 
comprehensive management plan can improve quality of life and function. 
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Standardizing care can also facilitate planning for multicenter trials and reveal 
aspects of care that require attention. 
Care of the person with PKAN requires anticipatory guidance for the person affected 
and their family, monitoring for complications and management of the neurological 
symptoms. In this guideline, we have focused more on PKAN-specific problems and 
their management. Many of the non-specific problems that are associated with 
chronic neurological diseases can occur in PKAN as well. Routine monitoring and 
proactive prevention efforts are important to initiate in order to minimize these 
risks. 
The following are guidelines for the symptomatic management of PKAN, namely 
orthopedic, respiratory, gastrointestinal, nutritional, pain and palliative care issues, 
as well as treatment strategies for commonly encountered medical problems and 
emergencies. Given the limited published literature in this area, the majority of 
recommendations are based on the expert opinion of clinicians with experience in 
the care of people with PKAN. We have not included standard approaches to 
addressing common problems where recommendations are not specific to PKAN. 
Feeding 
Difficulty with eating is almost universal in PKAN. In the child with classic disease, 
this typically manifests with progressive difficulty with mastication and swallowing 
that can initially be managed with diet modification, but which eventually 
compromises nutritional status in almost all cases. Many older individuals with 
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atypical PKAN exhibit eating dystonia, an unusual action-induced dystonia in which 
the tongue or jaw freezes during the act of mastication, requiring sensory tricks or 
manual manipulation of the food in the mouth to overcome. These techniques, along 
with diet modification, are often sufficient to maintain nutritional status in 
individuals with atypical disease. Speech, feeding and swallowing therapy may also 
help with specific issues. However, if a person can no longer maintain an adequate 
diet orally due to dysphagia or respiratory complications, insertion of a gastrostomy 
tube is recommended. Placement should precede the occurrence of significant weight 
loss (10% of normal body weight) or complications from aspiration. Most people 
still can enjoy food by mouth, but tube feeding can be utilized for the majority of 
their nutrition to provide adequate caloric intake. In our experience, some families 
may resist gastrostomy tube insertion because emotionally they relate it to a sign of 
disease progression, failure or simply “giving up.” We recommend setting 
expectations early in disease that a feeding tube may be necessary at some point as a 
useful measure to optimize quality of life by allowing time for activities other than 
oral feeds (which can be slow, ineffective, and tiring). Emphasizing G-tube 
placement as a routine disease management strategy rather than an end-of-life 
intervention may help alleviate such stress and anxiety. In our experience, many 
families who initially resisted the implementation of a feeding tube have later 
shared that they felt significant relief after gastrostomy placement, reporting that 
they could be more certain of adequate nutrition, that it was safer than oral feeding 
in people who were at risk of aspiration, and that quality of life was improved both 
for the person with PKAN and the caregivers. 
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Severely abnormal posturing may lead to difficulty in maintenance of g-tube 
placement and in re-insertion. Careful attention to proper re-insertion and 
monitoring of placement are important. 
 
Nutrition, diet and supplements 
Several factors can impact nutrition in PKAN including feeding problems, gastro-
intestinal dysmotility and chronic gastro-esophageal reflux. In addition, people with 
PKAN have increased energy expenditure and many require 5-10% more calories to 
maintain a healthy weight than calculated based solely on age and gender.42 
 
Nutritional requirements are otherwise based on age and general health. There is no 
evidence of clinical benefit from any specific dietary modifications or nutritional 
supplements in PKAN. We recommend against a low iron diet as it leads to systemic 
iron deficiency without significantly impacting brain iron levels. A healthy 
nutritionally complete diet is recommended. 
 
A ketogenic diet has been tried by a few families, but only mixed anecdotal reports 
are available. There is no convincing evidence of any effect, good or bad, in people 
with PKAN based on very limited information. In mice with defective pantothenate 
kinase 2, a ketogenic diet significantly worsened their general health and function as 
predicted based on increased demand for coenzyme A for mitochondrial fatty acid 
oxidation.11 As a result, we recommend against a ketogenic diet for all people with 
PKAN. We support families in their desire to try experimental nutritional 
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supplements as long as the risks are predicted to be low and they understand the 
uncertainty of those predictions.  
 
Dental and oral health 
Trauma to the mouth, tongue, jaw and teeth is very common in PKAN, resulting from 
orobuccolingual dystonia, tongue-biting, and direct impact as a result of falls. Jaw-
opening and jaw–closing dystonia can be disabling and very painful, with attendant 
risks of temporomandibular joint damage or dislocation, severe tongue-biting and 
biting injuries to the hands and lips with risk for secondary infection. When sensory 
tricks are ineffective, botulinum toxin can be effective in managing oral dystonia and 
is a first-line treatment to consider; otolaryngologists may be most experienced 
with the injection techniques needed for a good outcome, especially for jaw-opening 
dystonia, which is especially challenging to treat without increasing dysphagia and 
the risk of aspiration. Bite blocks affixed to the teeth or a bite-guard may be effective 
in preventing tongue-biting as long as the block does not become a choking hazard. 
In extreme circumstances, full-mouth dental extraction has provided relief from 
tongue- or lip-biting when jaw-closing dystonia is difficult to control. However, 
because dental procedures, like other medical procedures, carry some risk of 
precipitating a dystonic crisis in the person with PKAN, we recommend a generally 
conservative approach to dental care. In addition to attention to daily oral hygiene 
practice and regular dental care, we recommend consultation with otolaryngology 
and oral surgery experts when indicated.  
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Drooling 
Drooling (sialorrhea) is common in PKAN as a result of jaw-opening dystonia, which 
interferes with swallowing. Most people manage the problem with bibs in children 
or a towel on hand to wipe saliva. This simple approach is often sufficient to manage 
drooling. Anticholinergic agents, including trihexyphenidyl, commonly used to treat 
dystonia in PKAN, may decrease saliva production as a side effect that can lessen 
drooling. Glycopyrrolate, hyoscine patch, or botulinum toxin injections into the 
parotid and submandibular glands may be considered if absolutely necessary, but 
we do not routinely recommend medical or surgical interventions for drooling unless 
there is significant morbidity arising from this symptom. 
 
Vision 
Visual impairment is common in PKAN but disability from this feature lags behind 
that from the neurological disease for most people. There are adults with PKAN for 
whom the retinopathy seems to dominate the clinical phenotype for many years 
however. Ocular features include pigmentary retinopathy, abnormalities of eye 
movements and pupillary function, and blepharospasm.43 Most children and some 
adults will manifest poor vision in low-light conditions and constricted visual fields; 
these features may contribute to falls. While electrophysiologic abnormalities are 
commonly detected by electroretinogram (ERG), the results are of no clear clinical 
utility for most people with PKAN, and we do not recommend ERG except in rare 
cases where it is clinically indicated. Regular clinical ophthalmologic examinations are 
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recommended. Where blepharospasm is disabling, botulinum toxin injections should 
be employed as a first-line treatment. 
 
Respiratory care 
The respiratory complications of PKAN are similar to those associated with other 
chronic diseases that cause severe motor dysfunction. These include aspiration 
pneumonia and restricted pulmonary function from skeletal deformities. Stridor 
caused by laryngeal dystonia may compromise respiratory function; therefore this 
complication warrants close monitoring. Its management has been discussed in a 
prior section. Close attention to and regular monitoring of respiratory function is 
indicated for all people with PKAN. We recommend a pulmonary hygiene regimen if 
the person with PKAN has difficulty handling secretions or is otherwise considered to 
be at risk for aspiration. 
Rehabilitation and mobility 
People with PKAN develop abnormal tone to varying degrees, depending on the 
course and severity of their disease. Dystonia, spasticity, reduced joint mobility and 
contractures can all develop. Maintenance of range of motion in all joints is 
fundamental to care in order to facilitate optimal function, maintain good posture, 
promote ambulation for as long as possible, and minimize the development of fixed 
deformities and secondary complications of contractures. Physical therapists, 
occupational therapists, speech therapists and physicians with expertise in 
rehabilitation are all crucial to the multidisciplinary model of care. Regular 
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evaluation by individuals with expertise in rehabilitation medicine is crucial to 
maintaining functional abilities in PKAN. 
Durable medical equipment is often beneficial and must be tailored to each 
individual’s needs and goals. Regular review of equipment for fit and function is 
essential to meet changing needs. Many people with PKAN need devices to aid safe 
general mobility required for daily activities including orthotics, walkers, adapted 
strollers, manual and electric wheelchairs, standers and gait trainers. Assessment of 
the local environment at home, school and work is essential to allow adaptations 
where needed. 
 
Exercise 
Although there are no data to support a specific type of exercise program for people 
with PKAN, we recommend implementing an exercise program early in the disease 
course that can be adjusted as functional abilities change. There are no data to 
support a need for exercise restriction in PKAN. The main aims are to provide 
regular effective stretching and strengthening routines that are individualized for 
each person’s needs. Fluctuations in dystonia should guide therapy day-to-day. 
Sustaining weight-bearing activities for as long as possible in the disease (for 
example with standers and gait trainers) may help to preserve bone mass and 
reduce the risk of fractures. 
 
Management of skeletal complications 
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People with PKAN are at greater risk of skeletal complications secondary to 
abnormal limb tone (dystonia, spasticity), reduced mobility and osteopenia. They 
should therefore be monitored by clinical examination for spinal deformity, hip 
subluxation and dislocation, spinal cord lesions, and fractures. Baclofen pump 
placement, commonly used for dystonia management in PKAN, may accelerate the 
rate of scoliotic change, as in other disorders,44 although not all studies support 
this.45,46 The approach to monitoring and management follows general guidelines 
for people with similar disabilities. Despite concerns that the extreme opisthotonic 
posturing observed in children with PKAN could increase the risk of catheter 
kinking and subsequent baclofen withdrawal syndrome, the authors have not 
observed this.  
Fractures are common in PKAN, and an increase in dystonia or distress should always 
prompt a systematic assessment for occult fracture. Although there are no studies 
documenting decreased bone mass or increased fracture risk in people with PKAN, 
osteopenia is common in other non-ambulatory populations, and our experience 
indicates that pathologic/fragility fractures in PKAN are commonly associated with 
minor trauma or severe dystonia. This observation suggests that bone mass is 
decreased despite the significant stress from dystonia. For baseline bone health 
assessment, a dual energy x-ray absorptiometry (DEXA) scan is useful. Encouraging 
optimal weight-bearing activities in addition to appropriate intake of calcium and 
vitamin D are recommended. Many examples of children with acute worsening of 
their dystonia have ultimately been attributed to an occult fracture that was missed 
for many days. Attention to this risk is therefore of paramount importance. Use of 
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soft casts rather than plaster casts for fracture management will lessen 
complications from the specific device. 
 
Speech, Language and Communication 
The very young child with classic PKAN may have delayed speech and language 
development as part of a larger picture of intellectual and developmental disability. 
Even with intensive therapy, some children do not catch up to their peers in 
language abilities. Additionally, intellectual and motor dysfunction may make 
alternative methods of communication challenging in classic disease. In older 
children and adults with PKAN, language ability is not usually affected but 
dysarthria, palilalia, tachyphemia and hypophonia are common speech disabilities. 
In these individuals, speech therapy and the use of augmentative communication 
devices are valuable tools for preserving communication. Motor dysfunction may 
interfere with the utility of some devices, but the drive to communicate usually 
allows people to overcome their increasing limitations and find effective ways to 
make their needs and wants known to others. Pacing speech with either hand 
tapping or a delayed feedback device can improve palilalia and tachyphemia and 
preserve intelligible speech. Speech therapy consultation early in disease, including 
with an augmentative communication specialist if available, can help to preserve the 
widest range of means for communication. 
 
Pain management 
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Although many people with PKAN are reported by family members to have a high 
pain tolerance, dystonia often causes pain and agitation. Pain can, in turn, worsen 
dystonia and lead to a cycle that can be difficult to break. The prominence of 
dystonia in PKAN, in conjunction with impaired communication, complicates 
assessment and management. For these reasons it is especially important to carefully 
and systematically assess for treatable causes of pain with every exacerbation of 
dystonia. Pathologic fractures, occult gastrointestinal bleeding, occult infection, 
pressures sores, and joint subluxation or dislocation are recognized risks in PKAN 
that must be excluded. Once treatable causes have been considered and dystonia 
management optimized, controlling pain for comfort becomes the central goal. The 
choice of medications to manage pain is not specific to PKAN and should consider 
age, other medications, and respiratory and general state of health. Early 
involvement of pain specialists, including pediatric and adult palliative care teams, 
can ease suffering. 
 
Sleep  
A good sleeping pattern is fundamental to optimizing quality of life and mood and to 
reducing fatigue, pain and anxiety. Sleep disturbance is not normally an issue early 
in the disease course of PKAN nor is it a significant issue for most children. In adults 
later in their course of disease, reduced sleep time and lower efficacy of sleep have 
been reported,47 as have been periods of difficulty with arousal from sleep. As 
neurological symptoms progress, healthy sleep may be compromised by 
medications or pain. Although dystonia disappears in sleep, the person with PKAN 
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may have difficulty getting comfortable at sleep onset and changing position during 
the night, and thus may have poor quality sleep. Identifying and addressing any 
issues interfering with sleep in addition to developing a good sleep regimen and 
environment will be beneficial. When adjunctive therapies are needed, melatonin or 
chloral hydrate may improve sleep induction. Adding clonazepam or another 
benzodiazepine at night or changing the timing of an existing dose to bedtime may 
serve to both sedate the person with PKAN and lessen dystonia and spasticity.  
 
Seizures 
Since seizures are not a specific feature of PKAN,16 their occurrence should be 
presumed to be unrelated to the primary disease process, and their management 
should follow a standard approach. 
 
Sexual health and reproduction 
Adults with PKAN are able to have sexually fulfilling relationships. Reproductive 
capabilities seem to differ between men and women with PKAN. Women with PKAN 
have conceived and delivered healthy children without complications. Men with 
PKAN have fathered children; however, data suggest that men with PKAN may have 
defects in sperm motility, shape and number, all factors likely to decrease fertility 
(Hayflick, unpublished). Despite this, contraception is recommended for both men 
and women with PKAN who do not wish to conceive. Recommendations for specific 
types of contraception are the same as for people without PKAN.  
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Psychiatric and behavioral care 
Psychiatric disabilities affect most adolescents and adults with atypical PKAN. These 
problems often manifest before a diagnosis is established and may complicate the 
diagnostic odyssey. Common symptoms include impulsivity, obsessive-compulsive 
disorder, emotional lability, anxiety and depression.2,48 Attention deficit 
hyperactivity disorder (ADHD) is a common phenotypic feature of PKAN in 
children,1,33,49 and some children may benefit from treatment. Rarely, psychosis may 
manifest prior to or after onset of neurological symptoms.49-52 The inclusion of a 
psychiatrist in the medical team can help address these issues in a timely manner. 
Cognitive behavioral therapy may benefit people with PKAN. Although atypical 
neuroleptics may sometimes be indicated for management of behavioral and 
psychiatric complications of PKAN, their propensity to precipitate or aggravate 
parkinsonism and induce acute and tardive dystonia mandates caution in their use 
in this population. 
 
Emergency Care Plan for people with PKAN  
An emergency plan is a comprehensive set of instructions for families that outlines 
when, where, who, and how to contact emergency personnel should the person with 
PKAN need emergent care. This plan also provides critical information for 
emergency providers. The plan should list the person’s diagnoses with baseline 
findings, current medications, known drug allergies, immunization status, common 
presenting problems with specific suggested management strategies, and contact 
information for subspecialty providers. If any medical devices have been implanted 
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(e.g., DBS electrode, intrathecal baclofen pump), then include emergency contact 
information for each care team as well as the manufacturer’s contact information, 
and be sure to inform first-responders of the presence of these devices. Setting up 
an emergency care plan and maintaining a current emergency information form for 
the person with PKAN is recommended. Including a link to or copy of this Guideline 
may also be helpful to the medical team providing emergent care to an individual 
with PKAN.  
The American Academy of Pediatrics has developed an emergency information form 
for children with special needs that would be suitable for children and adults with 
PKAN (http://www.acep.org/Clinical---Practice-Management/Emergency-
Information-Form-for-Children-With-Special-Health-Care-Needs/). Maintaining a 
current emergency information form will ensure that a person’s complicated 
medical history is concisely summarized and available when it is needed most. This 
form should be completed with the treating physician and should be reviewed and 
updated at least annually. 
 
Immunization 
For children and adults with PKAN, the standard approach to immunization for 
people with similar disabilities should be followed. There are no known 
immunologic effects from PKAN that would alter response to or contraindicate 
immunization.  
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Education  
For all people with PKAN, addressing ongoing and changing educational needs is a 
high priority. School provides valuable educational and social opportunities. 
Therefore every effort to accommodate special needs should be made with the goal of 
maximizing function. Educational resources must be assessed frequently and 
adjusted as the disease progresses. Interval assessments should include 
neuropsychological evaluation that takes into account motor difficulties.53,54 Many 
people with PKAN will qualify for tailored educational programs that ensure a child 
with disability is attending a primary or secondary educational institution that is 
able to meet their specific needs and optimize their learning environment. Tailored 
education programs should also include physical, occupational and speech therapy 
when appropriate.  
Other issues that need attention in a school setting include: adaptations for gait 
difficulty and wheelchair use; management of attention deficit hyperactivity 
disorder and other neuropsychiatric symptoms; limitations from impairment of 
vision and speech; need for augmentative communication resources; and assistance 
with feeding and toileting. 
People with milder forms of PKAN may graduate from college, join training 
programs, or enter the work force. Maximizing opportunities for intellectual and 
social engagement is an important goal. Because academic success can be impacted 
by neuropsychiatric disabilities, attention to their management will contribute to 
success in school and at the workplace. 
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Psychosocial Support 
Providing adequate support for families at the time of diagnosis is important, and 
ongoing input is also necessary as families cope with this chronic, progressive 
disease. Isolation is a frequent challenge in older teenagers and young adults with 
PKAN, who have progressive limitations with independent communication and 
mobility. Support systems in place for such people vary between countries but can 
include daytime activity or work programs and young adult respite programs. Such 
programs have additional benefit in providing respite for caregivers, usually family 
members. Connecting with other teenagers and young adults through the NBIA 
Alliance can also be very useful. Caregivers can also find support through this 
network from others facing similar challenges and share ideas and experiences 
through family meetings, listservs, and other forums (see Key Resources below). 
Finally, as PKAN progresses, some people will be referred for hospice or palliative 
care with a focus on pain management and quality of life.  The modern model of 
pediatric palliative care can be an excellent resource for both medical and 
psychosocial support. 
 
Palliative and end-of-life care  
Palliative care for people with PKAN can ease suffering as their disabilities worsen. 
Early involvement of the palliative care team is encouraged and can be sought 
anytime after diagnosis. Care is focused on improving quality of life through relief of 
symptoms and provision of psychological, social, and spiritual care, a consideration 
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sometimes overlooked for children and young adults. Palliative medicine can be 
provided in conjunction with routine medical care (including ongoing treatment) at 
any stage in an illness. When appropriate, the palliative care team is also 
responsible for formulating a personalized end-of–life plan expressing the will of 
the person and family, as well as how to plan the end of life in a critical or 
emergency situation. The plan is likely to change over time, requiring different 
considerations as disease progresses. An advanced directive can be prepared with 
the help of palliative care professionals, which conveys preferences, wishes, beliefs 
and values for end-of-life decisions, including brain and tissue donation for 
research. Such statements will greatly assist clinicians in caring for people with 
limited communicative or decision-making capacity.55-58 
 
The role of NBIA lay advocacy organizations 
In our experience, most families eventually seek contact with other PKAN families 
and become part of this community, but many are not ready to do so initially 
following the diagnosis. The NBIA Alliance is an international federation of family 
advocacy organizations for NBIA disorders. As of 2016, the Alliance included 
organizations from eight countries including Canada, France, Germany, Italy, the 
Netherlands, Spain, Switzerland and the United States of America. Sharing a 
common vision, the Alliance members work together to raise awareness of NBIA 
disorders and to promote and support research. They offer opportunities for 
families to connect and share their experiences. Email forums, restricted-access 
Facebook groups, networking programs, and an international meeting place on 
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RareConnect (https://www.rareconnect.org/en/community/neurodegeneration-
with-brain-iron-accumulation-nbia) facilitate discussions among individuals and 
families from around the world. Family meetings, held at regular intervals and in 
varying locations, provide updates to families on the latest research and treatments 
and promote networking and support through speakers, workshops and social 
gatherings for both adults and children. Contact with these organizations can be 
made via their websites, telephone, mail, or email. See the Key Resources section for 
more information. 
 
Concluding remarks 
As we learn more about the natural history of PKAN and enter the era of disease-
modifying therapeutics, our recommendations will change to reflect these advances. 
This guideline is intended to be a living document that will benefit from continual 
review and revision. We look forward to a time when our interventions 
fundamentally change the course of this devastating disease.  
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Figure legends: 
Figure 1: Characteristic brain MRI changes in PKAN. A) Normal brain T2-weighted 
axial section showing normal signal in globus pallidus. B) PKAN brain showing a 
central hyperintense signal region surrounded by a region of signal hypointensity in 
the globus pallidus. 
Figure 2: Overview of the management of status dystonicus in PKAN. DSAP, dystonia 
severity action plan; GPi, Globus pallidus internus; ITB, intrathecal baclofen; DBS, 
deep brain stimulation; CK, creatine kinase; ICU, intensive care unit; HDU, high 
dependency unit; IV, intravenous.  
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Key Resources 
NBIAcure.org  Information for families, physicians and scientists 
NBIAdisorders.org Information, support, research opportunities 
NBIAalliance.org International alliance of NBIA patient advocacy groups 
TIRCON.eu Information for physicians and scientists on the work of the 
TIRCON consortium (Treat Iron-Related Childhood-Onset 
Neurodegeneration)  
 
  
07 Nov 2016 FINAL 43 
References 
1. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of 
neurodegeneration with brain iron accumulation. Journal of medical genetics 2009; 
46(2): 73-80. 
2. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic 
delineation of Hallervorden-Spatz syndrome. The New England journal of medicine 
2003; 348(1): 33-40. 
3. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A 
novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz 
syndrome. Nat Genet 2001; 28(4): 345-9. 
4. Hartig MB, Hortnagel K, Garavaglia B, et al. Genotypic and phenotypic 
spectrum of PANK2 mutations in patients with neurodegeneration with brain iron 
accumulation. Ann Neurol 2006; 59(2): 248-56. 
5. Sethi KD, Adams RJ, Loring DW, el Gammal T. Hallervorden-Spatz syndrome: 
clinical and magnetic resonance imaging correlations. Ann Neurol 1988; 24(5): 692-
4. 
6. Baumeister FA, Auer DP, Hortnagel K, Freisinger P, Meitinger T. The eye-of-
the-tiger sign is not a reliable disease marker for Hallervorden-Spatz syndrome. 
Neuropediatrics 2005; 36(3): 221-2. 
7. Chiapparini L, Savoiardo M, D'Arrigo S, et al. The "eye-of-the-tiger" sign may 
be absent in the early stages of classic pantothenate kinase associated 
neurodegeneration. Neuropediatrics 2011; 42(4): 159-62. 
07 Nov 2016 FINAL 44 
8. Delgado RF, Sanchez PR, Speckter H, et al. Missense PANK2 mutation without 
"eye of the tiger" sign: MR findings in a large group of patients with pantothenate 
kinase-associated neurodegeneration (PKAN). Journal of magnetic resonance 
imaging : JMRI 2012; 35(4): 788-94. 
9. Tomic A, Petrovic I, Svetel M, Dobricic V, Dragasevic Miskovic N, Kostic VS. 
Pattern of disease progression in atypical form of pantothenate-kinase-associated 
neurodegeneration (PKAN) - Prospective study. Parkinsonism & related disorders 
2015; 21(5): 521-4. 
10. Rana A, Seinen E, Siudeja K, et al. Pantethine rescues a Drosophila model for 
pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci U S A 2010; 
107(15): 6988-93. 
11. Brunetti D, Dusi S, Giordano C, et al. Pantethine treatment is effective in 
recovering the disease phenotype induced by ketogenic diet in a pantothenate 
kinase-associated neurodegeneration mouse model. Brain : a journal of neurology 
2014; 137(Pt 1): 57-68. 
12. Srinivasan B, Baratashvili M, van der Zwaag M, et al. Extracellular 4'-
phosphopantetheine is a source for intracellular coenzyme A synthesis. Nat Chem 
Biol 2015; 11(10): 784-92. 
13. Dooling EC, Schoene WC, Richardson EP, Jr. Hallervorden-Spatz syndrome. 
Archives of neurology 1974; 30(1): 70-83. 
14. Cossu G, Abbruzzese G, Matta G, et al. Efficacy and safety of deferiprone for 
the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and 
07 Nov 2016 FINAL 45 
neurodegeneration with brain iron accumulation (NBIA): results from a four years 
follow-up. Parkinsonism & related disorders 2014; 20(6): 651-4. 
15. Zorzi G, Zibordi F, Chiapparini L, et al. Iron-related MRI images in patients 
with pantothenate kinase-associated neurodegeneration (PKAN) treated with 
deferiprone: results of a phase II pilot trial. Mov Disord 2011; 26(9): 1756-9. 
16. Gregory A, Hayflick SJ. Pantothenate Kinase-Associated Neurodegeneration. 
In: Pagon RA, Adam MP, Ardinger HH, et al., eds. GeneReviews(R). Seattle (WA); 
2002, updated 2013. 
17. Schramm BM, Orser BA. Dystonic reaction to propofol attenuated by 
benztropine (cogentin). Anesth Analg 2002; 94(5): 1237-40, table of contents. 
18. Balas I, Kovacs N, Hollody K. Staged bilateral stereotactic 
pallidothalamotomy for life-threatening dystonia in a child with Hallervorden-Spatz 
disease. Mov Disord 2006; 21(1): 82-5. 
19. Hinkelbein J, Kalenka A, Alb M. Anesthesia for patients with pantothenate-
kinase-associated neurodegeneration (Hallervorden-Spatz disease) - a literature 
review. Acta Neuropsychiatr 2006; 18(3-4): 168-72. 
20. Sinha R, Biyani G, Bhattacharjee S. Anaesthetic management of a child with 
panthothenate kinase-associated neurodegeneration. Indian J Anaesth 2015; 59(1): 
43-6. 
21. Albright AL, Ferson SS. Intraventricular baclofen for dystonia: techniques and 
outcomes. Clinical article. Journal of neurosurgery Pediatrics 2009; 3(1): 11-4. 
07 Nov 2016 FINAL 46 
22. Rocque BG, Leland Albright A. Intraventricular vs intrathecal baclofen for 
secondary dystonia: a comparison of complications. Neurosurgery 2012; 70(2 Suppl 
Operative): 321-5; discussion 5-6. 
23. Turner M, Nguyen HS, Cohen-Gadol AA. Intraventricular baclofen as an 
alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes 
and technical considerations. Journal of neurosurgery Pediatrics 2012; 10(4): 315-9. 
24. Castelnau P, Zilbovicius M, Ribeiro MJ, Hertz-Pannier L, Ogier H, Evrard P. 
Striatal and pontocerebellar hypoperfusion in Hallervorden-Spatz syndrome. 
Pediatr Neurol 2001; 25(2): 170-4. 
25. Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as 
a mode of treatment of early onset pantothenate kinase-associated 
neurodegeneration. European journal of paediatric neurology : EJPN : official journal 
of the European Paediatric Neurology Society 2009; 13(1): 61-4. 
26. Timmermann L, Pauls KA, Wieland K, et al. Dystonia in neurodegeneration 
with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain : a 
journal of neurology 2010; 133(Pt 3): 701-12. 
27. Air EL, Ostrem JL, Sanger TD, Starr PA. Deep brain stimulation in children: 
experience and technical pearls. Journal of neurosurgery Pediatrics 2011; 8(6): 566-
74. 
28. Lumsden DE, Kaminska M, Gimeno H, et al. Proportion of life lived with 
dystonia inversely correlates with response to pallidal deep brain stimulation in 
both primary and secondary childhood dystonia. Developmental medicine and child 
neurology 2013; 55(6): 567-74. 
07 Nov 2016 FINAL 47 
29. Kaminska M, Lumsden DE, Ashkan K, Malik I, Selway R, Lin JP. Rechargeable 
deep brain stimulators in the management of paediatric dystonia: well tolerated 
with a low complication rate. Stereotactic and functional neurosurgery 2012; 90(4): 
233-9. 
30. Tsukamoto H, Inui K, Taniike M, et al. A case of Hallervorden-Spatz disease: 
progressive and intractable dystonia controlled by bilateral thalamotomy. Brain Dev 
1992; 14(4): 269-72. 
31. Justesen CR, Penn RD, Kroin JS, Egel RT. Stereotactic pallidotomy in a child 
with Hallervorden-Spatz disease. Case report. J Neurosurg 1999; 90(3): 551-4. 
32. Kyriagis M, Grattan-Smith P, Scheinberg A, Teo C, Nakaji N, Waugh M. Status 
dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and 
pallidotomy. Journal of paediatrics and child health 2004; 40(5-6): 322-5. 
33. Nardocci N, Rumi V, Combi ML, Angelini L, Mirabile D, Bruzzone MG. Complex 
tics, stereotypies, and compulsive behavior as clinical presentation of a juvenile 
progressive dystonia suggestive of Hallervorden-Spatz disease [letter]. Mov Disord 
1994; 9(3): 369-71. 
34. Scarano V, Pellecchia MT, Filla A, Barone P. Hallervorden-Spatz syndrome 
resembling a typical Tourette syndrome. Mov Disord 2002; 17(3): 618-20. 
35. Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for 
Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur 
Child Adolesc Psychiatry 2011; 20(4): 173-96. 
36. Allen NM, Lin JP, Lynch T, King MD. Status dystonicus: a practice guide. 
Developmental medicine and child neurology 2014; 56(2): 105-12. 
07 Nov 2016 FINAL 48 
37. Fasano A, Bove F, Lang AE. The treatment of dystonic tremor: a systematic 
review. J Neurol Neurosurg Psychiatry 2014; 85(7): 759-69. 
38. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive 
dystonia. A long-term follow-up study of 107 cases. Brain : a journal of neurology 
1998; 121 ( Pt 11): 2053-66. 
39. Rafizadeh S, Long JL. Pantothenate kinase-associated neurodegeneration 
causing paradoxical vocal fold motion. J Voice 2013; 27(5): 642-3. 
40. Blitzer A, Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. 
Ann Otol Rhinol Laryngol 1991; 100(2): 85-9. 
41. Grillone GA, Blitzer A, Brin MF, Annino DJ, Jr., Saint-Hilaire MH. Treatment of 
adductor laryngeal breathing dystonia with botulinum toxin type A. The 
Laryngoscope 1994; 104(1 Pt 1): 30-2. 
42. Williams S, Gregory A, Hogarth P, Hayflick SJ, Gillingham MB. Metabolism and 
energy requirements in pantothenate kinase-associated neurodegeneration. 
Molecular genetics and metabolism 2013; 110(3): 336-41. 
43. Egan RA, Weleber RG, Hogarth P, et al. Neuro-ophthalmologic and 
electroretinographic findings in pantothenate kinase-associated neurodegeneration 
(formerly Hallervorden-Spatz syndrome). American journal of ophthalmology 2005; 
140(2): 267-74. 
44. Ginsburg GM, Lauder AJ. Progression of scoliosis in patients with spastic 
quadriplegia after the insertion of an intrathecal baclofen pump. Spine 2007; 
32(24): 2745-50. 
07 Nov 2016 FINAL 49 
45. Senaran H, Shah SA, Presedo A, Dabney KW, Glutting JW, Miller F. The risk of 
progression of scoliosis in cerebral palsy patients after intrathecal baclofen therapy. 
Spine 2007; 32(21): 2348-54. 
46. Shilt JS, Lai LP, Cabrera MN, Frino J, Smith BP. The impact of intrathecal 
baclofen on the natural history of scoliosis in cerebral palsy. J Pediatr Orthop 2008; 
28(6): 684-7. 
47. Fantini ML, Cossu G, Molari A, et al. Sleep in genetically confirmed 
pantothenate kinase-associated neurodegeneration: a video-polysomnographic 
study. Parkinson's disease 2010; 2010: 342834. 
48. Pellecchia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype 
of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64(10): 
1810-2. 
49. Marelli C, Piacentini S, Garavaglia B, Girotti F, Albanese A. Clinical and 
neuropsychological correlates in two brothers with pantothenate kinase-associated 
neurodegeneration. Mov Disord 2005; 20(2): 208-12. 
50. del Valle-Lopez P, Perez-Garcia R, Sanguino-Andres R, Gonzalez-Pablos E. 
Adult onset Hallervorden-Spatz disease with psychotic symptoms. Actas espanolas 
de psiquiatria 2011; 39(4): 260-2. 
51. Oner O, Oner P, Deda G, Icagasioglu D. Psychotic disorder in a case with 
Hallervorden-Spatz disease. Acta psychiatrica Scandinavica 2003; 108(5): 394-7; 
discussion 7-8. 
07 Nov 2016 FINAL 50 
52. Pawar Y, Kalra G, Sonavane S, Shah N. A case of Hallervorden-Spatz disease 
presenting as catatonic schizophrenia. Indian journal of psychiatry 2013; 55(4): 386-
9. 
53. Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual 
and adaptive behaviour functioning in pantothenate kinase-associated 
neurodegeneration. Journal of intellectual disability research : JIDR 2007; 51(Pt. 6): 
417-26. 
54. Mahoney R, Selway R, Lin JP. Cognitive functioning in children with 
pantothenate-kinase-associated neurodegeneration undergoing deep brain 
stimulation. Developmental medicine and child neurology 2011; 53(3): 275-9. 
55. Levetown M, American Academy of Pediatrics Committee on B. 
Communicating with children and families: from everyday interactions to skill in 
conveying distressing information. Pediatrics 2008; 121(5): e1441-60. 
56. Lotz JD, Jox RJ, Borasio GD, Fuhrer M. Pediatric advance care planning: a 
systematic review. Pediatrics 2013; 131(3): e873-80. 
57. Lotz JD, Jox RJ, Borasio GD, Fuhrer M. Pediatric advance care planning from 
the perspective of health care professionals: a qualitative interview study. Palliat 
Med 2015; 29(3): 212-22. 
58. Morstad Boldt A, Yusuf F, Himelstein BP. Perceptions of the term palliative 
care. J Palliat Med 2006; 9(5): 1128-36.
07 Nov 2016 FINAL 51 
Author contributions 
Penelope Hogarth, Allison Gregory, Susan J. Hayflick:  literature search, figures, 
study design, data collection, data analysis, data interpretation, writing, and editing 
of manuscript. 
Manju A. Kurian: study design, writing, and editing of manuscript 
Barbara Csányi, Tamara Zagustin, Tomasz Kmiec, Patricia Wood, Angelika Klucken, 
Natale Scalise, Francesca Sofia, Thomas Klopstock, Giovanna Zorzi, Nardo Nardocci: 
writing and editing of manuscript  
 
 
  
07 Nov 2016 FINAL 52 
 
  
Figure 1. 
07 Nov 2016 FINAL 53 
 
Figure 2. 
